Spravato is the brand name for esketamine, a derivative of ketamine that works differently from traditional antidepressants. This FDA-approved treatment works differently than conventional medications, often providing rapid symptom improvement for those who haven’t responded to other approaches. Treatment-resistant depression (TRD) affects individuals who have tried multiple antidepressants without experiencing significant improvement in their symptoms. Spravato offers a new form of treatment that can break through this resistance, often providing relief when other treatments have failed.
